40,297 Moderna, Inc. $MRNA Shares Sold by New York Life Investment Management LLC

Posted by Brenda Bartman on Nov 12th, 2026

New York Life Investment Management LLC lowered its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 44.2% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 50,938 shares of the company’s stock after selling 40,297 shares during the quarter. New York Life Investment Management LLC’s holdings in Moderna were worth $9,809,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in MRNA. Costello Asset Management INC boosted its position in Moderna by 7.3% in the 3rd quarter. Costello Asset Management INC now owns 966 shares of the company’s stock valued at $186,000 after buying an additional 66 shares during the last quarter. Physician Wealth Advisors Inc. grew its stake in shares of Moderna by 8.3% during the third quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock valued at $171,000 after acquiring an additional 68 shares in the last quarter. Fortitude Family Office LLC increased its position in shares of Moderna by 53.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after acquiring an additional 77 shares during the last quarter. TD Waterhouse Canada Inc. increased its position in shares of Moderna by 2.6% during the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock worth $246,000 after acquiring an additional 85 shares during the last quarter. Finally, SteelPeak Wealth LLC lifted its stake in shares of Moderna by 3.9% in the third quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company’s stock worth $654,000 after acquiring an additional 127 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the sale, the president owned 1,525,858 shares in the company, valued at $219,921,913.54. The trade was a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 197,251 shares of company stock worth $33,875,904. Corporate insiders own 10.80% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $248.69 on Thursday. The firm has a fifty day moving average of $198.57 and a two-hundred day moving average of $94.60. The firm has a market cap of $100.63 billion, a P/E ratio of -35.03 and a beta of 1.16. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $280.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $890.25 million. During the same quarter in the prior year, the business posted ($0.51) EPS. The company’s revenue for the quarter was up 29.2% on a year-over-year basis. As a group, research analysts anticipate that Moderna, Inc. will post -5.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

MRNA has been the subject of a number of analyst reports. Morgan Stanley increased their price target on Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Barclays lifted their price objective on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a report on Monday, August 24th. JPMorgan Chase & Co. upped their target price on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Piper Sandler reiterated an “overweight” rating and set a $305.00 target price (up from $230.00) on shares of Moderna in a research note on Monday. Finally, Singular Research upgraded Moderna to a “hold” rating in a research note on Wednesday, September 23rd. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, Moderna has an average rating of “Hold” and an average target price of $113.75.

Get Our Latest Stock Analysis on Moderna

Latest Moderna News

Here’s some of the latest news about MRNA:

Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year and above estimates, and beat the consensus EPS forecast. The company also raised its full-year revenue-growth outlook, providing the clearest near-term catalyst for the recent share strength. Why is Moderna stock soaring today
Neutral Sentiment: Brookline Capital Markets kept a Buy rating and raised its 2026–2028 EPS estimates, although it still projects losses in those years. Moderna analyst estimate revisions
Negative Sentiment: Brookline lowered its fourth-quarter 2026 EPS estimate to a loss of $2.87 per share from a projected loss of $2.09, signaling weaker near-term earnings expectations despite its improved full-year and later-year forecasts. Moderna analyst estimate revisions

Moderna Company Profile

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.